Bramlage, Carsten

[["dc.bibliographiccitation.firstpage","76"],["dc.bibliographiccitation.issue","3"],["dc.bibliographiccitation.journal","DMW - Deutsche Medizinische Wochenschrift"],["dc.bibliographiccitation.lastpage","81"],["dc.bibliographiccitation.volume","136"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Cuneo, A."],["dc.contributor.author","Haertel, D."],["dc.contributor.author","Jung, K."],["dc.contributor.author","Witteck, C.-H."],["dc.contributor.author","Hoegel, R."],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Bramlage, Peter"],["dc.contributor.author","Tebbe, Ulrich"],["dc.date.accessioned","2018-11-07T09:01:06Z"],["dc.date.available","2018-11-07T09:01:06Z"],["dc.date.issued","2011"],["dc.description.abstract","Background and objective: Angioplasty in patients with renal artery stenosis aims at reducing blood pressure and at improving kidney function. Its efficacy has however been questioned by recent published data. It was the aim of this retrospective study to compare angioplasty with medical treatment in an unselected patient population. Methods: Data on 109 patients were retrospectively anlysed. This cohort included all those patients admitted to the Lippe-Detmold Hospital between 1992 and 2008 for renal artery stenosis. The data included blood pressure, creatinine-based calculated glomerular filtration rate (cGFR), any renal dialysis, cardiovascular risk factors, events and survival time after transluminal renal angioplasty or drug treatment, respectively. Results: Patients who had undergone angioplasty were younger (p = 0.04), had less cardiovascular co-morbidity (p < 0.01), but a higher degree of stenosis (p < 0.01). After a median follow-up of 32.5 (angioplasty) and 36.0 months (drug treatment), respectively, a significant decrease of cGFR was recorded in drug treated patients (- 16.2 ml/min, 95%, CI - 25.7 to - 6.7) but not in the angioplasty group (- 4.5 ml/min, 95%, CI - 13.5 to 4.5). There were no other significant differences were not observed. Conclusion: Younger patients with a high degree of renal artery stenosis but without generalized atherosclerosis more frequently underwent angioplasty in clinical practice. The smaller post-angioplasty reduction in the loss of renal function in this group needs to be validated in a prospective, randomized study."],["dc.identifier.doi","10.1055/s-0030-1269442"],["dc.identifier.isi","000286135500002"],["dc.identifier.pmid","21225553"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/24334"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.relation.issn","0012-0472"],["dc.title","Renal artery stenosis: angioplasty or drug treatment?"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","S8"],["dc.bibliographiccitation.issue","46"],["dc.bibliographiccitation.journal","DMW - Deutsche Medizinische Wochenschrift"],["dc.bibliographiccitation.lastpage","S9"],["dc.bibliographiccitation.volume","132"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Bevandaf, J."],["dc.contributor.author","Maatouk, I."],["dc.contributor.author","Koziolek, Michael Johann"],["dc.contributor.author","Lauterberg, Christina"],["dc.contributor.author","Strutz, Frank M."],["dc.date.accessioned","2018-11-07T10:52:57Z"],["dc.date.available","2018-11-07T10:52:57Z"],["dc.date.issued","2007"],["dc.identifier.isi","000251423500025"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/49234"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Georg Thieme Verlag Kg"],["dc.publisher.place","Stuttgart"],["dc.relation.issn","0012-0472"],["dc.title","BMP-5 is expressed in renal interstitial fibroblasts and has TGF-beta neutralizing effect in vitro"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","401"],["dc.bibliographiccitation.issue","6"],["dc.bibliographiccitation.journal","Scandinavian Journal of Rheumatology"],["dc.bibliographiccitation.lastpage","409"],["dc.bibliographiccitation.volume","37"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Kaps, C."],["dc.contributor.author","Ungethuem, U."],["dc.contributor.author","Bramlage, Peter"],["dc.contributor.author","Koziolek, Michael Johann"],["dc.contributor.author","Wessels, Johannes Theodor"],["dc.contributor.author","Krenn, V."],["dc.contributor.author","Pruss, Axel"],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Strutz, Frank M."],["dc.contributor.author","Burmester, Gerd-Ruediger"],["dc.contributor.author","Haeupl, T."],["dc.date.accessioned","2018-11-07T11:20:44Z"],["dc.date.available","2018-11-07T11:20:44Z"],["dc.date.issued","2008"],["dc.description.abstract","Objective: Growth differentiation factor-5 (GDF-5), a member of the transforming growth factor (TGF)-beta family, is involved in joint development during embryogenesis and has the potential to regenerate cartilage in adult animals. As progression of chronic joint diseases is influenced by cytokines of the synovial tissue, we examined the expression and effects of GDF-5 in this tissue. Methods: Microarray experiments were investigated for differential expression of GDF-5 in synovial tissues, synovial fibroblasts, and peripheral blood cells. GDF-5 expression was validated by semiquantitative reverse transcriptase polymerase chain reaction (RT-PCR), immunohistochemistry, double immunofluorescence, and in situ hybridization in synovial tissue of normal donors (ND) and patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Effects of inflammation and therapy were investigated in RA and OA fibroblasts after stimulation with interleukin (IL)-1 beta, tumour necrosis factor (TNF)-alpha, methotrexate (MTX), and prednisolone. The influence of GDF-5 on macophages was studied by chemotaxis assay. Results: Microarray analysis and immunostaining revealed expression predominantly in synovial fibroblasts. Compared to patients without immunomodulating drugs, expression of GDF-5 was decreased significantly in patients receiving glucocorticoids and/or disease-modifying antirheumatic drugs (DMARDs) (p=0.007), but did not differ between the total group of ND, OA, and RA. Stimulation with prednisolone and TNF alpha reduced GDF-5 expression in OA and RA fibroblasts, whereas MTX and IL-1 beta revealed minor or no relevant change. GDF-5 also reduced cell migration of macrophages (p<0.001). Conclusion: GDF-5 is expressed in synovial fibroblasts and may counteract macrophage infiltration. Its modulation by inflammation and therapy suggests that glucocorticoids play a conflicting role by suppressing not only inflammation but also putative mechanisms of repair."],["dc.identifier.doi","10.1080/03009740802120010"],["dc.identifier.isi","000262270200001"],["dc.identifier.pmid","18830904"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/55613"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Taylor & Francis As"],["dc.relation.issn","0300-9742"],["dc.title","Modulatory effects of inflammation and therapy on GDF-5 expression in rheumatoid arthritis synovium"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.journal","Journal of Hypertension"],["dc.bibliographiccitation.volume","26"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Schlumbohm, Christina"],["dc.contributor.author","Amann, Kerstin"],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Strutz, Frank M."],["dc.date.accessioned","2018-11-07T11:14:45Z"],["dc.date.available","2018-11-07T11:14:45Z"],["dc.date.issued","2008"],["dc.format.extent","S154"],["dc.identifier.isi","000257197001070"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/54209"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Lippincott Williams & Wilkins"],["dc.publisher.place","Philadelphia"],["dc.relation.conference","18th Scientific Meeting of the European-Society-of-Hypertension/22nd Scientific Meeting of the International-Society-of-Hypertension"],["dc.relation.eventlocation","Berlin, GERMANY"],["dc.relation.issn","0263-6352"],["dc.title","The prenatal exposure of dexamethason in marmoset monkeys does not result in hypertension"],["dc.type","conference_abstract"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","142"],["dc.bibliographiccitation.issue","1"],["dc.bibliographiccitation.journal","Transplantation Proceedings"],["dc.bibliographiccitation.lastpage","147"],["dc.bibliographiccitation.volume","45"],["dc.contributor.author","Heeg, Malte"],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Homayounfar, Kia"],["dc.contributor.author","Muehlhausen, Johannes"],["dc.contributor.author","Leha, Andreas"],["dc.contributor.author","Koziolek, Michael Johann"],["dc.date.accessioned","2018-11-07T09:30:22Z"],["dc.date.available","2018-11-07T09:30:22Z"],["dc.date.issued","2013"],["dc.description.abstract","Background. The most common immunosuppressive regimens after renal transplantation include calcineurin inhibitors (CNI). However, due to renal toxicity long-term graft survival does not seem to be positively affected by CNIs. Methods. In the present study, we investigated 17 patients, in which the CM immunosuppression was converted to a CM-free, mycophenolate sodium (MPS) regimen. Conversion was performed due to progressive impairment of the graft function from suspected CM toxicity. We retrospectively analyzed graft function as well as toxicity and surrogate markers for 4 years before and 4 years after conversion using a repeated-measures mixed model data analysis and/or a paired sample t-test. Results. The mean time point of therapy conversion was 11.2 +/- 4.6 years after transplantation. Within 1 month of CNI discontinuation, allograft function improved significantly, remaining at a significant level for 2 years. The estimated glomerular filtration rate increased from 43.4 +/- 14.8 to a maximum of 55.7 +/- 21.7 mL/min at 1 year after conversion (P = .0027). After 4 years, the end of the observation period, renal function was similar to the baseline. There were no significant side effects. Conclusion. These data suggested that, when chronic CM-toxicity is suspected, renal allograft recipients may benefit from CM withdrawal in favor of a MPS-including immunosuppressive regimen."],["dc.identifier.doi","10.1016/j.transproceed.2012.10.028"],["dc.identifier.isi","000315007200025"],["dc.identifier.pmid","23375288"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/31288"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Inc"],["dc.relation.issn","1873-2623"],["dc.relation.issn","0041-1345"],["dc.title","Improvement of Renal Graft Function After Conversion From a Calcineurin Inhibitor Including Immunosuppression to a Mycophenolate Sodium Including Regimen: A 4-year Follow-up"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","235"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of Clinical Apheresis"],["dc.bibliographiccitation.lastpage","242"],["dc.bibliographiccitation.volume","29"],["dc.contributor.author","Strauchmann, Julia"],["dc.contributor.author","Wallbach, Manuel"],["dc.contributor.author","Bramlage, Carsten"],["dc.contributor.author","Puls, Miriam"],["dc.contributor.author","Konstantinides, Stavros V."],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Koziolek, Michael Johann"],["dc.date.accessioned","2018-11-07T09:34:08Z"],["dc.date.available","2018-11-07T09:34:08Z"],["dc.date.issued","2014"],["dc.description.abstract","Lipoprotein apheresis (LA) is believed to exert anti-atherosclerotic effects beyond LDL-cholesterol reduction. We investigated 22 patients undergoing regular LA on a weekly basis (group A) before (AP) and after LA procedure (EP), 15 healthy individuals (group B), and 22 hyperlipoproteinemic patients with concomitant cardiovascular end organ damage treated without LA therapy (group C). Biomarkers of endothelial inflammation (hsCRP), plaque destabilization, and rupture (sVCAM, MMP-9, PAPP-A, ADMA) were quantified. Intergroup comparison revealed a statistically significant lower MMP-9 level in group A (AP and EP) compared with group C (P<0.01), whereas PAPP-A levels were lower in group B compared with group A and C (P=0.04). EP ADMA-levels and EP sVCAM levels in group A were statistically lower compared with group B and C. AP and EP values comparison revealed a significant reduction for hsCRP (mean 41.0 +/- 16.7%, P<0.01), sVCAM (mean 69.6 +/- 14.0%, P<0.01), PAPP-A (mean 88.7 +/- 20.4%, P<0.01), ADMA (mean 69.7 +/- 18.4% P<0.01). In conclusion, we observed a transient decrease in the plasma concentrations of several biomarkers expressed during plaque destabilization and elevated cardiovascular risk after a single LA treatment. J. Clin. Apheresis 29:235-242, 2014. (c) 2013 Wiley Periodicals, Inc."],["dc.identifier.doi","10.1002/jca.21311"],["dc.identifier.isi","000343831500001"],["dc.identifier.pmid","24281903"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/32112"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell"],["dc.relation.issn","1098-1101"],["dc.relation.issn","0733-2459"],["dc.title","Lipoprotein Apheresis Reduces Biomarkers of Plaque Destabilization and Cardiovascular Risk"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","647"],["dc.bibliographiccitation.issue","5"],["dc.bibliographiccitation.journal","Journal of Nephrology"],["dc.bibliographiccitation.lastpage","655"],["dc.bibliographiccitation.volume","24"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Tampe, Bjoern"],["dc.contributor.author","Bevanda, Jelena"],["dc.contributor.author","Maatouk, Imad"],["dc.contributor.author","Koziolek, Michael"],["dc.contributor.author","Lange, Katharina"],["dc.contributor.author","Ahrens, Katharina"],["dc.contributor.author","Schmid, Holger"],["dc.contributor.author","Cohen, Clemens D."],["dc.contributor.author","Bramlage, Peter"],["dc.contributor.author","Kretzler, Matthias"],["dc.contributor.author","Strutz, Frank M."],["dc.date.accessioned","2018-11-07T08:51:58Z"],["dc.date.available","2018-11-07T08:51:58Z"],["dc.date.issued","2011"],["dc.description.abstract","Background: Bone morphogenetic protein-5 (BMP-5) has been shown to be essential for nephrogenesis. Its role in adult kidney and in patients with hypertensive nephrosclerosis is still unknown. Methods: BMP-5 expression was evaluated by immunostaining and real-time PCR in tissue samples from normal and nephrosclerotic human kidneys. The impact of transforming growth factor-beta (TGF-beta), tumor necrosis factor-alpha (TNF-alpha) and angiotensin-II (AT-II) on expression of BMP-5 and its receptors was quantified in proximal tubular cells (HK-2). Functional characteristics of BMP-5 were evaluated by testing its influence on TGF-beta-induced epithelial-to-mesenchymal transition (EMT), TNF-alpha-induced apoptosis of HK-2 cells and inflammatory cell infiltration. Results: BMP-5 expression was localized in tubular epithelial cells and significantly decreased in nephrosclerotic kidneys. Stimulation of HK-2 cells with TGF-beta, TNF-alpha and AT-II resulted in a significant decreased expression of BMP-5 and its receptors. BMP-5 attenuated TGF-beta-induced EMT, TNF-alpha-induced apoptosis and migration of mononuclear cells. Conclusions: BMP-5 is expressed in the tubuli of adult kidneys. Its decreased expression in nephrosclerosis along with its regenerative capabilities in HK-2 cells may point to a protective role in hypertensive nephrosclerosis."],["dc.identifier.doi","10.5301/JN.2011.6330"],["dc.identifier.isi","000296976000016"],["dc.identifier.pmid","21319131"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/22061"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wichtig Editore"],["dc.relation.issn","1121-8428"],["dc.title","The role of bone morphogenetic protein-5 (BMP-5) in human nephrosclerosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","143"],["dc.bibliographiccitation.issue","2"],["dc.bibliographiccitation.journal","Therapeutic Apheresis and Dialysis"],["dc.bibliographiccitation.lastpage","152"],["dc.bibliographiccitation.volume","14"],["dc.contributor.author","Koziolek, Michael Johann"],["dc.contributor.author","Hennig, Ulrich"],["dc.contributor.author","Zapf, Antonia"],["dc.contributor.author","Bramlage, Carsten"],["dc.contributor.author","Grupp, Clemens"],["dc.contributor.author","Armstrong, Victor William"],["dc.contributor.author","Strutz, Frank M."],["dc.contributor.author","Mueller, Georg Anton"],["dc.date.accessioned","2018-11-07T08:44:57Z"],["dc.date.available","2018-11-07T08:44:57Z"],["dc.date.issued","2010"],["dc.description.abstract","We retrospectively analyzed 10 906 lipid apheresis sessions (heparin-induced lipoprotein precipitation, direct adsorption of lipoproteins, double filtration plasmapheresis, dextran sulfate adsorption, and immunoadsorption) in 38 patients who were consecutively treated in our department during the last 20 years. The incidences of major cardiovascular events (MACE) (death, cerebrovascular accident, myocardial infarction, limb amputation, and renal vascular involvement) were taken separately as primary end-points or as a combined end-point. The time-course of secondary end-points (coronary and extracranial status of arteries, left ventricular function, occlusive artery disease, and calculated glomerular filtration rate [cGFR]) were also evaluated, as well as the extent of the reduction in plasma lipids and lipoproteins and the incidence of therapy associated side-effects. MACE decreased from 7.02% events per patient per year at the start of lipid apheresis to 1.17% during lipid apheresis and the rate of myocardial revascularization decreased from 22.8% to 3.8% per patient per year. Classical (diabetes mellitus, arterial hypertension, and smoking history), as well as novel risk factors (cGFR < 60 mL/min, statin withdrawal, mixed hyperlipoproteinemia, and elevated lipoprotein (a)) were associated with an elevated risk for MACE. All applied methods had comparable effects. All lipid apheresis methods proved to be safe and suitable for long-term treatment. The present data demonstrate that treatment with lipid apheresis is very effective and leads to long-term reduction in cardiovascular mortality and morbidity."],["dc.identifier.doi","10.1111/j.1744-9987.2009.00747.x"],["dc.identifier.isi","000276036600003"],["dc.identifier.pmid","20438535"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/20314"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Wiley-blackwell Publishing, Inc"],["dc.relation.issn","1744-9979"],["dc.title","Retrospective Analysis of Long-term Lipid Apheresis at a Single Center"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.artnumber","31"],["dc.bibliographiccitation.journal","BMC Nephrology"],["dc.bibliographiccitation.volume","11"],["dc.contributor.author","Bramlage, Carsten Paul"],["dc.contributor.author","Tampe, Bjoern"],["dc.contributor.author","Koziolek, Michael"],["dc.contributor.author","Maatouk, Imad"],["dc.contributor.author","Bevanda, Jelena"],["dc.contributor.author","Bramlage, Peter"],["dc.contributor.author","Ahrens, Katharina"],["dc.contributor.author","Lange, Katharina"],["dc.contributor.author","Schmid, Holger"],["dc.contributor.author","Cohen, Clemens D."],["dc.contributor.author","Kretzler, Matthias"],["dc.contributor.author","Mueller, Georg Anton"],["dc.date.accessioned","2018-11-07T08:36:49Z"],["dc.date.available","2018-11-07T08:36:49Z"],["dc.date.issued","2010"],["dc.description.abstract","Background: Bone Morphogenetic Protein (BMP)-7 is protective in different animal models of acute and chronic kidney disease. Its role in human kidneys, and in particular hypertensive nephrosclerosis, has thus far not been described. Methods: BMP-7 mRNA was quantified using real-time PCR and localised by immunostaining in tissue samples from normal and nephrosclerotic human kidneys. The impact of angiotensin (AT)-II and the AT-II receptor antagonist telmisartan on BMP-7 mRNA levels and phosphorylated Smad 1/5/8 (pSmad 1/5/8) expression was quantified in proximal tubular cells (HK-2). Functional characteristics of BMP-7 were evaluated by testing its influence on TGF-beta induced epithelial-to-mesenchymal transition (EMT), expression of TGF-beta receptor type I (TGF-beta RI) and phosphorylated Smad 2 (pSmad 2) as well as on TNF-alpha induced apoptosis of proximal tubular cells. Results: BMP-7 was predominantly found in the epithelia of the distal tubule and the collecting duct and was less abundant in proximal tubular cells. In sclerotic kidneys, BMP-7 was significantly decreased as demonstrated by real-time PCR and immunostaining. AT-II stimulation in HK-2 cells led to a significant decrease of BMP-7 and pSmad 1/5/8, which was partially ameliorated upon co-incubation with telmisartan. Only high concentrations of BMP-7 (100 ng/ml) were able to reverse TNF-alpha-induced apoptosis and TGF-beta-induced EMT in human proximal tubule cells possibly due to a decreased expression of TGF-beta RI. In addition, BMP-7 was able to reverse TGF-beta-induced phosphorylation of Smad 2. Conclusions: The findings suggest a protective role for BMP-7 by counteracting the TGF-beta and TNF-alpha-induced negative effects. The reduced expression of BMP-7 in patients with hypertensive nephrosclerosis may imply loss of protection and regenerative potential necessary to counter the disease."],["dc.identifier.doi","10.1186/1471-2369-11-31"],["dc.identifier.isi","000208334700001"],["dc.identifier.pmid","21080950"],["dc.identifier.purl","https://resolver.sub.uni-goettingen.de/purl?gs-1/5802"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/18396"],["dc.notes.intern","Merged from goescholar"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Biomed Central Ltd"],["dc.relation.issn","1471-2369"],["dc.rights","CC BY 2.0"],["dc.rights.uri","https://creativecommons.org/licenses/by/2.0"],["dc.title","Bone Morphogenetic Protein (BMP)-7 expression is decreased in human hypertensive nephrosclerosis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dc.type.version","published_version"],["dspace.entity.type","Publication"]]

[["dc.bibliographiccitation.firstpage","754"],["dc.bibliographiccitation.issue","4"],["dc.bibliographiccitation.journal","Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics"],["dc.bibliographiccitation.lastpage","762"],["dc.bibliographiccitation.volume","1834"],["dc.contributor.author","Pesic, Ivana"],["dc.contributor.author","Mueller, Georg Anton"],["dc.contributor.author","Baumann, Cosima"],["dc.contributor.author","Dihazi, Gry Helene"],["dc.contributor.author","Koziolek, Michael Johann"],["dc.contributor.author","Eltoweissy, Marwa"],["dc.contributor.author","Bramlage, Carsten"],["dc.contributor.author","Asif, Abdul R."],["dc.contributor.author","Dihazi, Hassan"],["dc.date.accessioned","2018-11-07T09:26:27Z"],["dc.date.available","2018-11-07T09:26:27Z"],["dc.date.issued","2013"],["dc.description.abstract","The vast majority of patients with end-stage renal disease are treated with intermittent hemodialysis as a form of renal replacement therapy. To investigate the impact of hemodialysis membrane material on vital protein removal, dialysates from 26 well-characterized hemodialysis patients were collected 5 min after beginning, during 5 h of treatment, as well as 5 min before ending of the dialysis sessions. Dialysis sessions were performed using either modified cellulose (n = 12) (low-flux and high flux) or synthetic Polyflux (n=14) (low-flux and high-flux) dialyzer. Protein removal during hemodialysis was quantified and the dialysate proteome patterns were analyzed by 2-DE, MS and Western blot. There was a clear correlation between the type of membrane material and the amount of protein removed. Synthetic Polyflux membranes exhibit strong interaction with plasma proteins resulting in a significantly higher protein loss compared to modified cellulosic membrane. Moreover, the proteomics analysis showed that the removed proteins represented different molecular weight range and different functional groups: transport proteins, protease inhibitors, proteins with role in immune response and regulations, constructive proteins and as a part of HIA immune complex. The effect of this protein removal on hemodialysis treatment outcome should be investigated in further studies. (C) 2013 Elsevier B.V. All rights reserved."],["dc.identifier.doi","10.1016/j.bbapap.2013.01.021"],["dc.identifier.isi","000317452300005"],["dc.identifier.pmid","23369790"],["dc.identifier.uri","https://resolver.sub.uni-goettingen.de/purl?gro-2/30301"],["dc.notes.status","zu prüfen"],["dc.notes.submitter","Najko"],["dc.publisher","Elsevier Science Bv"],["dc.relation.issn","1570-9639"],["dc.title","Cellulose membranes are more effective in holding back vital proteins and exhibit less interaction with plasma proteins during hemodialysis"],["dc.type","journal_article"],["dc.type.internalPublication","yes"],["dc.type.peerReviewed","yes"],["dc.type.status","published"],["dspace.entity.type","Publication"]]